Augmented Concentration of Isopentyl-Deoxynyboquinone in Tumors Selectively Kills NAD(P)H Quinone Oxidoreductase 1-Positive Cancer Cells through Programmed Necrotic and Apoptotic Mechanisms.
Jiangwei WangXiaolin SuLingxiang JiangMatthew W BoudreauLindsay E ChatkewitzJessica A KilgoreKashif Rafiq ZahidNoelle S WilliamsYaomin ChenShaohui LiuPaul J HergenrotherXiumei HuangPublished in: Cancers (2023)
Lung and breast cancers rank as two of the most common and lethal tumors, accounting for a substantial number of cancer-related deaths worldwide. While the past two decades have witnessed promising progress in tumor therapy, developing targeted tumor therapies continues to pose a significant challenge. NAD(P)H quinone oxidoreductase 1 (NQO1), a two-electron reductase, has been reported as a promising therapeutic target across various solid tumors. β-Lapachone (β-Lap) and deoxynyboquinone (DNQ) are two NQO1 bioactivatable drugs that have demonstrated potent antitumor effects. However, their curative efficacy has been constrained by adverse effects and moderate lethality. To enhance the curative potential of NQO1 bioactivatable drugs, we developed a novel DNQ derivative termed isopentyl-deoxynyboquinone (IP-DNQ). Our study revealed that IP-DNQ treatment significantly increased reactive oxygen species generation, leading to double-strand break (DSB) formation, PARP1 hyperactivation, and catastrophic energy loss. Notably, we discovered that this novel drug induced both apoptosis and programmed necrosis events, which makes it entirely distinct from other NQO1 bioactivatable drugs. Furthermore, IP-DNQ monotherapy demonstrated significant antitumor efficacy and extended mice survival in A549 orthotopic xenograft models. Lastly, we identified that in mice IP-DNQ levels were significantly elevated in the plasma and tumor compared with IB-DNQ levels. This study provides novel preclinical evidence supporting IP-DNQ efficacy in NQO1 + NSCLC and breast cancer cells.
Keyphrases
- drug induced
- liver injury
- reactive oxygen species
- breast cancer cells
- cell death
- small cell lung cancer
- clinical trial
- randomized controlled trial
- mesenchymal stem cells
- stem cells
- risk assessment
- rectal cancer
- advanced non small cell lung cancer
- dna repair
- signaling pathway
- replacement therapy
- cancer therapy
- epidermal growth factor receptor
- drug delivery
- tyrosine kinase
- smoking cessation